Table 1.
Studies including women with infertility and poor ovarian response or polycystic ovarian syndrome
| Study/publication year | Study duration (months) | Study population (n) | Mean age/range (years) | City, Country | Intervention group (CoQ10 daily dose/duration/ART commencement or hCG administration) (n) | Comparison group (n) |
|---|---|---|---|---|---|---|
| Women with infertility and poor ovarian response | ||||||
| Bentov/2014 | 30 | 39 women with POR undergoing IVF-ICSI [Intervention (17)/Control (22)] | 39/35–43 | Toronto, Canada | 600 mg/8 weeks/day 3 of the following menstrual cycle (17) | Placebo (22) |
| Caballero/2016 | Not mentioned |
78 women with POR undergoing IVF-ICSI [Intervention (39)/Control (39)] |
38/36–40 | Buenos Aires, Argentine | 1200 mg/12 weeks/beginning of the following menstrual cycle (39) | No-treatment (39) |
| Xu/2018 | 13 | 169 women with POR undergoing IVF-ICSI [Intervention (76)/Control (93)] | 32/28–36 | Beijing, China | 600 mg/8 weeks/beginning of the following menstrual cycle (76) | No-treatment (93) |
| Women with infertility and polycystic ovarian syndrome | ||||||
| El Refaeey /2014 | 36 | 101 women with PCOS, resistant to clomiphene citrate, undergoing ovarian stimulation and ovulation induction [Intervention (51)/Control (50)] | 21–35 /28 | Mansura, Egypt | 180 mg/2nd cycle day until hCG administration day/hCG given when ≥ 1 follicle of ≥ 18 mm (51) | No-treatment (50) |
| Sen Sharma/2017 | Not mentioned | 62 women with PCOS, resistant to clomiphene citrate, undergoing ovarian stimulation and ovulation induction [Intervention (32)/Control (30)] | 21–40 /30 | West Bengal, India | 180 mg/1st cycle day until hCG administration day/hCG given when ≥ 1 follicle of ≥ 18 mm (32) | No-treatment (30) |